An Open Label Phase 2 Study of Intravenously Administered Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases
A single-center, open-label, non-randomized phase I/II study to evaluate the efficacy, safety and tolerance of crizanlizumab monotherapy and in combination with nivolumab in patients with advanced glioblastoma (GB) who exhausted standard of care (SOC) therapy, patients with metastatic brain melanoma (MBM) and patients with newly diagnosed unmethylated GB. Subjects will be screened for up to 28 days prior to treatment initiation. Eligible subjects will be allocated to one of 3 cohorts: Cohort 1: Patients with metastatic melanoma with primarily diagnosed or newly progressing brain metastases who failed immunotherapy. Cohort 2: Patients with recurrent or progressing GB following primary radiation therapy and temozolomide. Patients may have failed up to 2 prior systemic treatment lines (including temozolomide as adjuvant therapy) and are candidates for further treatment. Cohort 3: Patients with newly diagnosed GB who were evaluated for methylguanine-DNA methyltransferase(MGMT) methylation status and have un-methylated MGMT promotor-therefore, they are not candidates for maintenance temozolomide therapy.
• Age ≥ 18 years.
• Estimated life expectancy at least 3 months
• Have metastatic melanoma with primarily diagnosed or newly progressing brain metastases.
• Was treated with 1 prior systemic line of immunotherapy - either PD-1 inhibitor monotherapy or combined CTLA4 and PD-1 antibodies or another investigational combination of immunotherapy. Patients with BRAF-mutant melanoma who have also received BRAF mutation targeted therapy are also eligible.
• Have failed prior immunotherapy line, either due to primary resistance or acquired resistance.
• Have measurable disease defined by RECIST criteria and have at least one, non-previously irradiated brain metastasis of at least 1-cm short diameter. Otherwise, previously irradiated lesions should present with enlargement following radiation therapy.
• Is clinically stable with no neurological deficits. Patients may receive steroid supportive therapy up to 10 mg of prednisone or the equivalent.
• Have Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
• Adequate organ function defined by blood tests for blood count and chemistry.
⁃ Women of childbearing potential practicing an acceptable method of birth control.
⁃ Understand study procedures and willingness to comply for the entire duration of the study and to give written informed consent.
• Age ≥ 18 years.
• Estimated life expectancy at least 3 months
• Have with recurrent or persistent GB
• Received first line therapy with brain irradiation and maintenance temozolamide.
• Measurable disease per RANO criteria on brain MRI.
• Have Eastern Cooperative Oncology Group (ECOG) performance status \<2.
• Adequate organ function defined by blood tests for blood count and chemistry.
• Women of childbearing potential practicing an acceptable method of birth control.
• Understand study procedures and willingness to comply for the entire duration of the study and to give written informed consent.
• Age ≥ 18 years.
• Estimated life expectancy at least 3 months.
• Histologically confirmed newly diagnosed GB.
• Tumor test result shows MGMT unmethylated type.
• Received definitive brain irradiation.
• Patients may be treated with novo TTF (optune) per local standard.
• Have Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
• Adequate organ function defined by blood tests for blood count and chemistry.
• Women of childbearing potential practicing an acceptable method of birth control.
⁃ Understand study procedures and willingness to comply for the entire duration of the study and to give written informed consent.